Animalcare Group plc announced that, following a positive opinion received from the Committee for Medicinal Products for Veterinary Use (CVMP) as first announced on 18 February 2021, Daxocox (enflicoxib) has now been granted Marketing Authorisation for the European Union. Daxocox is approved in Europe for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Additionally, the Veterinary Medicines Directorate (VMD)has authorised Daxocox with the same indication for use in the United Kingdom. Available as a flavoured oral tablet, the dosing interval for the novel COX-2 inhibitor is once per week providing significant value and convenience through lasting relief from chronic and acute pain.